Amodiaquine+Artesunate vs. Artemether-Lumefantrine for Uncomplicated Malaria in Ghanaian Children

University of Ghana Medical School

Overview

Artemisinin combination therapies (ACT) are currently recommended for malaria treatment. Artemether-lumefantrine(A-L) and Artesunate+amodiaquine (A+A) have been the most commonly adopted of the recommended ACT regimens. In Ghana, A+A is the current first-line antimalarial treatment in Ghana, but there has been 1 efficacy report of this regimen in Ghana till date. Moreover, the safety of repeated treatments with ACT has been little studied. This study aims to evaluate the efficacy of A+A vs. A-L, as well as the safety of repeated treatments of these regimens in a longitudinal trial in which recruited children will be followed up for 1 year.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Conditions

Uncomplicated Malaria

Interventions

amodiaquine+artesunate/artemether-lumefantrineDRUG

Eligibility

Sex: ALLMin age: 6 MonthsMax age: 14 Years

Medical Language ↔ Plain English

Inclusion Criteria: * microscopically confirmed acute uncomplicated falciparum malaria; * temperature at screening 37.50C or more or history of fever 24 preceding enrollment; * willingness to comply with follow up schedule; * written informed consent by accompanying parent or guardian Exclusion Criteria: * features of severe malaria or danger signs of malaria * known intolerance or allergy to any of the study medications * known treatment with any of the study medications in the month preceding enrollment * serious underlying disease that may mask outcome assessment

Locations (1)

Korle Bu Teaching Hospital

Accra, Ghana

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.